Nilutamide
- Generic Name
- Nilutamide
- Brand Names
- Anandron, Nilandron
- Drug Type
- Small Molecule
- Chemical Formula
- C12H10F3N3O4
- CAS Number
- 63612-50-0
- Unique Ingredient Identifier
- 51G6I8B902
- Background
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
- Indication
用于已转移的前列腺癌，可与手术或化学去势合用。
- Associated Conditions
- Metastatic Prostate Cancer
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Conditions
- Castration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
- Interventions
- Procedure: OrchiectomyOther: Quality-of-Life AssessmentRadiation: Radiation TherapyProcedure: Radical Prostatectomy
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1273
- Registration Number
- NCT03678025
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Conditions
- Stage II Prostate Adenocarcinoma AJCC v7Stage I Prostate Adenocarcinoma AJCC v7Stage III Prostate Adenocarcinoma AJCC v7
- Interventions
- Radiation: External Beam Radiation TherapyOther: Laboratory Biomarker Analysis
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 612
- Registration Number
- NCT03070886
- Locations
- 🇵🇷
Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico
🇺🇸AdventHealth Celebration, Celebration, Florida, United States
🇺🇸GenesisCare USA - Aventura, Aventura, Florida, United States
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- Conditions
- Recurrent Prostate CarcinomaProstate Adenocarcinoma
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 310
- Registration Number
- NCT01786265
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Duke University
- Target Recruit Count
- 57
- Registration Number
- NCT00918385
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
- Conditions
- Adenocarcinoma of the ProstateRecurrent Prostate Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00512668
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Procedure: orchiectomyRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 361
- Registration Number
- NCT00002633
- Locations
- 🇨🇦
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 1386
- Registration Number
- NCT00003653
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 306
- Registration Number
- NCT00002855
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00028769
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020254
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.